Despite its competitive nature, the drug discovery sector has embraced collaboration successfully, says Benedict Cross, Chief Technology Officer at Phoremost. The drug discovery and biotechnology industry is historically a competitive arena, both intellectually and commercially, where the race to the finish line can be characterised by unseemly acts of avaricious… Read More
ERS Genomics and Nuvisan Innovation Campus Berlin (ICB), an integrated contract research service provider for drug discovery and early development programs, have announced a non-exclusive license agreement granting Nuvisan ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio. Nuvisan ICB originated from a spin-out of the major pharma R&D functions of… Read More
Listen to this article on the DDW Podcast: By Caroline Horizny, Taconic Biosciences When a pharmaceutical company, biotech firm, or academic institution embarks on a preclinical research project, one of the most critical early-stage decisions is which animal model will best support the project’s objective. Mouse models remain a go-to resource… Read More
Lu Rahman talks to John Fuller, Product Manager–Drug Discovery, Beckman Coulter Life Sciences about the pandemic’s impact on this global organisation and its customers — and what to expect in 2021 and beyond. Not surprisingly, the emergence of the Covid-19 pandemic in 2020 caused hundreds, if not thousands of drug… Read More
Horizon Discovery, a PerkinElmer company, announced that it is expanding its gene editing and modulation portfolio to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists to better understand the biological pathways, processes and pathologies of disease by repressing genes at the transcriptional… Read More
New research from scientists at the Wellcome Sanger Institute has shown a gene not previously linked to cancer plays a key role in the spread of certain cancers to the lungs. The team found that when the gene LRRN4CL was over-expressed in mice, the… Read More
ERS Genomics and Setsuro Tech have announced a non-exclusive license agreement granting Setsuro Tech access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan. Setsuro Tech has developed a high-throughput genome editing method for mammalian embryos, termed genome editing by electroporation of Cas9 protein (GEEP). Using this method, the company is… Read More
ERS Genomics and G+FLAS Life Sciences, a biotechnology company developing research tools and reagents associated with CRISPR technology, have announced a non-exclusive license agreement granting G+FLAS access to ERS Genomics’ CRISPR/Cas9 patent portfolio. G+FLAS supports research organisations by providing CRISPR-related biological research services, tools, and reagents. The Ccampany produces all… Read More
ERS Genomics and ZeClinics have announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio. ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier. ZeClinics is a contract research organisation using zebrafish to carry out services… Read More
This paid-for advertorial by Taconic Biosciences appeared in DDW Volume 22, Issue 1 – Winter 2020/21 In the following article, Dr. Caroline Horizny from Taconic Biosciences discusses the intellectual property landscape of CRISPR/Cas9-generated mouse models. The growing complexity of preclinical research for drug development has yielded an increase in the… Read More
Horizon can help researchers work with the biologically relevant cell models (immune cells, induced pluripotent derived cardiac and neural cells, and organoids) that closely mimic the end-stage biology of interest. With over a decade of CRISPR/Cas cell line engineering experience, Horizon’s iPSC editing platform is designed to enable efficient and… Read More
Mammoth Biosciences has announced an agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution comprising Agilent’s Bravo automation workstation and Mammoth Biosciences’ DETECTR BOOSTTM assay. Together, the DETECTR BOOSTTM SARS-CoV-2 kit and Agilent automated liquid handling system would provide a complete workflow for… Read More
Horizon Discovery is sponsoring SLAS 2021. The company will be holding an innovative tutorial presentation on booth 114 which will cover the use of both pooled and arrayed screens in the drug discovery pipeline. Topics covered include: Arrayed screens in primary immune cells with co-culture endpoints Pooled CRISPR knockout screens with… Read More
Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase expansion of its plasmid DNA services, a continuation of its gene therapy services’ project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ High Quality (HQ) DNA manufacturing capacity alongside new… Read More
Mammoth Biosciences has signed agreements with MilliporeSigma and Hamilton Company targeting commercialisation of a high-throughput CRISPR-based SARS CoV-2 test. The test leverages Mammoth’s DETECTR BOOST platform and will provide a sample-to-answer turnkey solution for commercial laboratories to enable an increase in testing capacity. As laboratories face limited capacity and testing… Read More
By Andrew Myers Throughout the pandemic, infectious disease experts and frontline medical workers have asked for a faster, cheaper and more reliable COVID-19 test. Now, leveraging the so-called “lab on a chip” technology and the cutting-edge genetic editing technique known as CRISPR, researchers at Stanford have created a highly automated… Read More
